Dave Stanforth has over 20 years of experience in IVD / CDx development working in both diagnostic companies and pharma. He worked at Dako / Agilent where he held leadership positions in CDx product development, program management and business development. He led the development of the first companion and complementary diagnostics for PD-1 / PD-L1 checkpoint inhibitors in partnership with Merck and BMS. He joined Daiichi Sankyo in 2017 where he led the development of CDx assays for Daiichi’s ADC portfolio. Dave is currently heading up Diagnostic Strategy and Development for Amgen and is the global team lead for the development of CDx assays for Amgen’s G12C targeted therapy AMG 510.